Ibrahim Mahmoud A A, Hassan Alaa M A, Abdelrahman Alaa H M, Mekhemer Gamal A H, Sidhom Peter A, Sayed Shaban R M, Abdelbacki Ashraf M M, Hegazy Mohamed-Elamir F
Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minya 61519, Egypt.
School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4000, South Africa.
J Trop Med. 2025 Jul 1;2025:1786204. doi: 10.1155/jotm/1786204. eCollection 2025.
Epstein-Barr nuclear antigen 1 (EBNA1) is an attractive therapeutic target for identifying pharmaceutical drug molecules to fight Epstein-Barr virus (EBV) contagion because of its key function in viral reproduction. To find potent EBNA1 inhibitors, the Naturally Occurring Plant-based Anticancer Compound-Activity-Target (NPACT) database, including > 1500 compounds, was filtered utilizing computational approaches. The efficiency of the docking technique used to anticipate the inhibitor-EBNA1 binding pose was initially evaluated based on obtainable experimental data. Upon the computed docking scores, molecular dynamics simulations (MDSs) were executed for the most superior NPACT compounds bound to EBNA1, accompanied by binding affinity estimations utilizing the MM/GBSA approach. According to binding affinity computations over 200 ns MDS, bitucarpin A demonstrated stronger Δ than KWG, an EBNA1 reference inhibitor, with values of -39.1 and -32.4 kcal/mol, respectively. Post-MD analyses assured the steadiness of bitucarpin A inside the EBNA1 binding pocket over 200 ns MDS. Besides, pharmacokinetics, physicochemical, and toxicity features were predicted for bitucarpin A and demonstrated its promising oral bioavailability. Density functional theory calculations were executed, and their outcomes substantiated the results given by docking and MDS computations. According to these findings, bitucarpin A showed promising inhibitory activity as a potent EBNA1 inhibitor that may be a prospective anti-EBV drug candidate.
爱泼斯坦-巴尔核抗原1(EBNA1)因其在病毒复制中的关键作用,是鉴定用于对抗爱泼斯坦-巴尔病毒(EBV)感染的药物分子的一个有吸引力的治疗靶点。为了找到有效的EBNA1抑制剂,利用计算方法对包含1500多种化合物的天然植物来源抗癌化合物-活性-靶点(NPACT)数据库进行了筛选。首先根据可获得的实验数据评估用于预测抑制剂与EBNA1结合构象的对接技术的效率。根据计算得到的对接分数,对与EBNA1结合的最优异的NPACT化合物进行分子动力学模拟(MDS),并使用MM/GBSA方法进行结合亲和力估计。根据超过200纳秒MDS的结合亲和力计算,比图卡品A表现出比EBNA1参考抑制剂KWG更强的Δ,其值分别为-39.1和-32.4千卡/摩尔。MD后分析确保了比图卡品A在超过200纳秒MDS的EBNA1结合口袋内的稳定性。此外,对比图卡品A的药代动力学、物理化学和毒性特征进行了预测,结果表明其具有良好的口服生物利用度。进行了密度泛函理论计算,其结果证实了对接和MDS计算给出的结果。根据这些发现,比图卡品A作为一种有效的EBNA1抑制剂显示出有前景的抑制活性,可能是一种潜在的抗EBV药物候选物。